Andra Elena Petcu1, Irina Magdalena Dumitru2, Roxana Carmen Cernat3, Carmen Ilie Șerban4, Aurelia Hangan1, Elena Ghiță5, Nicoleta Dorina Vlad6, Mirela Dumitrașcu4, Adriana Teodora Câmpeanu4, Sorin Rugină7. 1. MD, Clinical Infectious Diseases Hospital, Constanța, Doctoral School, Ovidius University of Constanța, 124 Mamaia boulevard, Constanţa, Romania. 2. MD, PhD, Associate Professor, Faculty of Medicine, Ovidius University of Constanța, 124 Mamaia boulevard, Constanţa, Clinical Infectious Diseases Hospital, Constanța, Romania. 3. MD, PhD, Assistant Professor, Faculty of Medicine, Ovidius University of Constanța, 124 Mamaia boulevard, Constanţa, Clinical Infectious Diseases Hospital, Constanța, Romania. 4. MD, Clinical Infectious Diseases Hospital, 100 Ferdinand boulevard, Constanța, 900178, Romania. 5. MD, County Hospital Mangalia, 3 Carol Davila street, Mangalia, Romania. 6. MD, Clinical Infectious Diseases Hospital, Constanța, Romania, Doctoral School, Ovidius University of Constanța, 124 Mamaia boulevard, Constanţa, Romania. 7. MD, PhD, Professor, Faculty of Medicine, Ovidius University of Constanța, 124 Mamaia boulevard, Constanţa, Clinical Infectious Diseases Hospital, Constanța, Romanian Academy of Scientists, Romanian Academy of Medical Sciences, Romania.
Abstract
INTRODUCTION: Thrombocytopenia is common in SARS-COV-2 infection, and about a quarter of cases have moderate thrombocytopenia. Severe thrombocytopenia is less common and is associated with severe forms of COVID-19. The pathogenesis of this thrombocytopenia appears to be complex, the immune mechanism being incriminated. Immune thrombocytopenic purpura (ITP) is one of the severe complications of COVID-19 and has an increased risk of mucosal or cutaneous bleeding. CASE REPORT: We present the case of a 72-year-old woman admitted to the hospital with moderate COVID-19 who developed severe thrombocytopenia 13 days after the onset of COVID symptoms. Nine days after admission, her platelets decreased from 149×109/L to 3×109/L and numerous patches appeared on the skin and mucous membranes. She was responsive to corticosteroids and platelet transfusion, after five days, the platelet level returned to normal. CONCLUSIONS: Close hematological monitoring of patients with COVID is necessary to prevent severe complications. Even if this patient did not receive immunoglobulins, corticosteroid therapy and platelet administration led to a favorable outcome. GERMS.
INTRODUCTION: Thrombocytopenia is common in SARS-COV-2 infection, and about a quarter of cases have moderate thrombocytopenia. Severe thrombocytopenia is less common and is associated with severe forms of COVID-19. The pathogenesis of this thrombocytopenia appears to be complex, the immune mechanism being incriminated. Immune thrombocytopenic purpura (ITP) is one of the severe complications of COVID-19 and has an increased risk of mucosal or cutaneous bleeding. CASE REPORT: We present the case of a 72-year-old woman admitted to the hospital with moderate COVID-19 who developed severe thrombocytopenia 13 days after the onset of COVID symptoms. Nine days after admission, her platelets decreased from 149×109/L to 3×109/L and numerous patches appeared on the skin and mucous membranes. She was responsive to corticosteroids and platelet transfusion, after five days, the platelet level returned to normal. CONCLUSIONS: Close hematological monitoring of patients with COVID is necessary to prevent severe complications. Even if this patient did not receive immunoglobulins, corticosteroid therapy and platelet administration led to a favorable outcome. GERMS.